Innoviva (INVA) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.

Which has more risk & volatility, FOLD or INVA?

Amicus Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Do analysts prefer FOLD or INVA?

Amicus Therapeutics presently has a consensus target price of $16.75, suggesting a potential upside of 94.43%. Innoviva has a consensus target price of $55.00, suggesting a potential upside of 214.59%. Given Innoviva's stronger consensus rating and higher probable upside, analysts clearly believe Innoviva is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings and valuation, FOLD or INVA?

Innoviva has lower revenue, but higher earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$528.30M	5.01	-$151.58M	-$0.18	-47.86
Innoviva	$358.71M	3.05	$179.72M	$0.19	92.02

Does the media prefer FOLD or INVA?

In the previous week, Amicus Therapeutics had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for Amicus Therapeutics and 3 mentions for Innoviva. Amicus Therapeutics' average media sentiment score of 1.31 beat Innoviva's score of 1.12 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in FOLD or INVA?

99.1% of Innoviva shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 1.7% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in FOLD or INVA?

Amicus Therapeutics received 228 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 57.58% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%
Innoviva	Outperform Votes 304 57.58%	Underperform Votes 224 42.42%

Is FOLD or INVA more profitable?

Innoviva has a net margin of 18.31% compared to Amicus Therapeutics' net margin of -10.62%. Innoviva's return on equity of 20.84% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-10.62%	12.44%	2.60%
Innoviva	18.31%	20.84%	11.38%

Summary

Amicus Therapeutics and Innoviva tied by winning 9 of the 18 factors compared between the two stocks.